Where things stand
The path from "an FDA advisory committee is looking at peptides" to "you can legally get one at a pharmacy" is longer and more specific than most coverage suggests. Here is exactly where things are - and where the decision that actually matters still lies ahead.
The FDA places a group of peptides - including BPC-157 - in "Category 2" of its interim review for pharmacy compounding under section 503A, citing significant safety concerns. In plain terms: they cannot be legally compounded. Demand, however, does not disappear.
Source: FDA 503A bulk-substances categories →Under HHS Secretary Robert F. Kennedy Jr., the FDA removes a set of peptides from Category 2 and refers them to its Pharmacy Compounding Advisory Committee for a formal review. Important: removal from Category 2 is not approval - it moves them into the review process.
Source: FiercePharma, 2026 →Comments filed to docket FDA-2025-N-6895 on or before this date are provided directly to the committee ahead of the meeting. Peppies filed its comment - urging that the safety cost of the unregulated status quo be weighed, and that any access come with rigorous testing standards.
Source: FDA docket FDA-2025-N-6895 →The public docket remains open through July 22, 2026. Late comments are still considered by the FDA but may not reach committee members before they vote.
Source: FDA docket (open through July 22) →The Pharmacy Compounding Advisory Committee meets at the FDA's White Oak campus to review seven peptides - BPC-157, KPV, TB-500 and MOTS-c on day one; DSIP/Emideltide, Semax and Epitalon on day two - and vote recommendations. These votes are advisory and non-binding. Meet the panel →
Source: FDA meeting notice →The FDA weighs the committee's recommendation - which it usually follows but is not required to. Notably, the agency's own career scientists have recommended against adding these peptides, citing insufficient safety data. The committee's advice and the staff review may not align.
Source: FDA briefing materials →Actually changing access requires the FDA to open formal rulemaking: a proposed rule, a public comment period, and a final rule - a process that can take more than a year. That later comment window is the one where an ordinary person's comment carries legal weight. Most people never hear it opened. We'll tell you the moment it does.
Source: how the 503A list is set (FDA) →